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CC BY-NC-ND license (http://creativeAbstract Genetic, environmental and demographic factors contribute to the development of
essential hypertension. Genetic polymorphism of Rennin-angiotensin-aldosterone system
(RAAS) has been extensively studied to determine the genetic susceptibility to hypertension.
The insertion/deletion (I/D) angiotensin converting enzyme (ACE) polymorphism has been es-
tablished as a cardiovascular risk factor in some population, but its association with essential
hypertension is controversial. This study sought to determine the association of I/D polymor-
phism of the ACE gene in south Indian essential hypertensive subjects. A total of 208 clinically
diagnosed essential hypertensive patients without any associated diseases and 220 healthy
control subjects were included in this study. Distribution and allelic frequency of Insertion
(I) and Deletion (D) polymorphism at the 287 base pair Alu repeat sequence in the intron 16
of ACE gene were analyzed. The distribution of II, ID, DD genotypes of ACE gene was 28.3%,
32.6% and 38.9% respectively in essential hypertensive patients and to 53.6%, 26.3% and 20%
in controls. The allele frequency for D allele is 0.58 in essential hypertension as compared
to 0.34 of control subjects. The genotype and allele frequency of ACE gene polymorphism is
significantly differed in patients when compared to controls. In conclusion, the I/D polymor-
phism of ACE gene is associated with Indian essential hypertension.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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160 R. Krishnan et al.IntroductionTable 1 Baseline characteristics of study population.
Variable Hypertension
(n Z 208)
Controls
(n Z 220)
Age (years) 43.6  5.6 42.78  5.7
Gender (M/F) 121/97 130/90
BMI (kg/m2) 26.12  3.2 25.3  4.1
SBP (mmHg) 151  9.8* 123.34  1.8
DBP (mmHg) 92.56  8.7* 69.89  5.0
BGL (mg/dl) 93  6* 89  4
Serum urea (mg/dl) 22.23  4.21 21.8  4.8
Serum creatinine
(mg/dl)
0.97  0.21 0.93  0.25
Serum sodium
(mmol/L)
140.1  3.2* 139.24  2.62
Serum potassium
(mmol/L)
3.72  0.21 3.66  0.32
Serum chloride
(mmol/L)
89.32  4.31 88.63  3.1
Total cholesterol
(mg/dl)
207  4.6* 157  6.8
LDL-Cholesterol
(mg/dl)
125.19  6.3* 85  4.5
HDL-Cholesterol
(mg/dl)
38.21  4.3* 53  3.2
Triglycerides (mg/dl) 168  8.3* 133  6.2
LDL-low density lipoprotein, HDL-high density lipoprotein.
*P Z <0.05 highly significant.Hypertension is a major public health problem in India and
in other developing countries.1 A meta analysis of hyper-
tension prevalence rates in India demonstrated a significant
increase.2 Prevalence of hypertension in India between
three and six decades increased about 30 times among
urban residents and by about 10 times among rural resi-
dents.3 The cause of essential hypertension is multifacto-
rial; genetic factors also a part of it.4
Genetic factors are responsible for about 30e60% of the
familial aggregation of blood pressure and the transmission
of cultural factors being responsible for the remaining
(stress, diet, physical activity).5 Blood pressure is mainly
regulated by Renin-angiotensin-aldosterone system (RAAS)
which also acts as a key regulator of electrolyte balance.6
Genetic polymorphism of RAAS has been thoroughly stud-
ied to elucidate the genetic susceptibility to Hypertension.7
The angiotensin converting enzyme (ACE) gene is the key
gene in RAAS and attractive candidate gene to study the
development of essential hypertension.8 Angiotensin con-
verting enzyme a metalloproteinase (dipeptidyl carboxy
peptidase) converts angiotensin-I to angiotensin-II, a
potent vasoconstrictor.9 The protease activity of ACE in-
activates bradykinin, a potent vasodilator.10 ACE consists of
1306 amino acids sequence.11
Angiotensin converting enzyme insertion/deletion (ACE
I/D) polymorphism is one of the well described poly-
morphism of the RAAS. Several recent studies have
demonstrated the association of ACE I/D polymorphism
with cardiovascular complications.12,13 On the other hand,
the association between I/D polymorphism and hyperten-
sion is still controversial. Some studies have shown the as-
sociation of ACE I/D polymorphism with essential
hypertension14e16 and some studies were failed to show the
association.17,18 ACE I/D polymorphism associated with
increased levels of ACE in plasma which increase Angio-
tensin II levels a key factor enhancing peripheral resis-
tance. The mean plasma ACE level in DD subject is about
twice that of II subject with ID subject having intermediate
level.19,20 Although the I/D polymorphism of the ACE gene is
considered to play a small role in the pathogenesis of hy-
pertension, the higher levels of ACE associated with the D
allele may lead to greater angiotensin II formation in car-
diac and vascular tissue, predisposing a subject to cardio-
vascular damage. There are very limited studies available
in Indian subjects regarding association of ACE I/D poly-
morphism in essential hypertension and the data was
lacking in the south Indian population. The present study
aimed to explore the association of I/D polymorphism of
ACE gene with south Indian essential hypertensive patients.
This study was conducted first time in the southern part of
the Andhra Pradesh (Nellore District) India.
Materials and methods
The study was approved by ethical committee of the Nar-
ayana Medical College and Hospital, Nellore, Andhra Pra-
desh, India. A total of 428 subjects were recruited for this
study and they were divided into two groups. Group-I
consist of 208 essential hypertensive patients attendingvarious clinics of Narayana Medical College and Hospital,
Nellore city. Group II consist of 220 healthy volunteers (no
age, sex matched controls) were collected randomly. Data
collected from each subjects as clinical variables including
age, height, weight, body mass index, and family history.
Hypertension was defined as a systolic blood pressure (SBP)
>140 mmHg and sustained diastolic blood pressure (DBP)
>90 mmHg. Blood pressure was measured in the subjects
who had been seated and rested for five minutes and taken
twice to calculate mean SBP and DBP. All the patients were
not receiving antihypertensive drugs and patients with
secondary hypertension, renal, liver and cardiac abnor-
malities were excluded from the present study.
Five milliliters of venous blood samples were collected
from each subject. A portion of the blood samples were
taken an EDTA tube (Becton Dickson, NJ, USA) to obtain
genomic DNA extraction, the rest was left to clot to obtain
serum and stored at 20 C for further analysis. Serum
samples were analyzed on a HUMASTAR-300 autoanalyser
(human, Germany) using kits supplied by human diagnostics
(GmbH, Germany) to determine the levels of fasting blood
glucose, serum urea, creatinine, total cholesterol, high
density lipoprotein cholesterol (HDL-C), triglycerides
(TGL). Low density lipoprotein cholesterol (LDL-C) calcu-
lated by Friedwald formula. Third report of the national
cholesterol education program guidelines (NCEP report
2001)34 were followed for the classification of lipid profile.
Serum sodium, potassium and chloride were estimated on
HUMLYTE electrolyte analyzer. (Ion selective electrode
method GmbH Germany).
Table 2 Distribution of ACE genotypes and allelic frequencies of the study population.
Study group ACE genotypes Total Allelic frequencies Total
II ID DD I D
Controls
n (%)
118 (53.6) 58 (26.3) 44 (20) 220 294 (0.66) 146 (0.34) 440
Patients
n (%)
59 (28.3) 68 (32.6) 81 (38.9) 208 186 (0.42) 230 (0.58) 416
Insertion/deletion polymorphism 161Genomic DNA was extracted from peripheral blood using
spin column genomic DNA extraction kit (Axygen Bio-
sciences, USA) and ACE intron 16 gene was amplified by
Polymerase chain reaction (MG series Thermocycler, USA).
For amplification, a flanking primer pair8 5
0
-CTGGA-
GACCACT CCCATCCTTTCT-3
0
and 5
0
-GATGTGGCCA TCA-
CATTC GTCACGAT-3
0
(synthesized by Bioserve
Biotechnology) was used. PCR amplification was performed
with a 50 ml reaction mixture contains 40 pmol of each
primer, 200 mmol/L each dNTP, 1.5 mmol/L Mgcl2, 1 U of
thermo stable DNA polymerase (DYNAZYME II Espoo,
Finland) and 20 mMol of Tris-HCL (pH 8.8 at 25 C) PCR
cycling conditions were carried out with an initial dena-
turation step of 5 min at 95 C, followed by 30 cycles of
denaturation at 95 C for 30 s, annealing at 58 C for
1 min and extension at 72 C for 2 min, followed by final
extension for 5 min at 72 C before the storage of sample at
4 C. PCR products were separated by agarose gel elec-
trophoresis (GENI Bangalore India). DNA fragments were
stained with ethidium bromide and visualized under UV
light (Gel documentation system Biorad, USA). The PCR
fragments consist of three genotypes, a 490 bp band (II), a
190 bp band (DD), and both 490 and 190 bp band (ID). To
increase the DD genotyping, PCR amplifications were also
performed with insertion specific primer pair21 5
0
-
TGGGACCACAGCGCCCGCCACTAC-3
0
and 5
0
-TCGCCAGCCCTC
CCATGCCCATAA-3
0
for each sample which had the DD ge-
notype to avoid mistyping of ID heterozygote’s as D homo-
zygote’s. PCR cycling conditions were carried out with an
initial denaturation step of 1 min at 95 C, followed by 30
cycles of denaturation at 95 C for 30 s, annealing at 67 C
for 45 s and extension at 72 C for 2 min. The PCR product
shows a 335 bp band for I allele and no band for DD
genotype.
Clinical characteristics data of all the subjects were
expressed as mean  SD. All the statistical analysis was
carried out using SPSS software version 15.0 for Microsoft
windows. Continuous variable was compared between the
cases and control group by using two tailed students ‘t’
test. Allelic frequencies were calculated by gene counting
method and the genotype distribution with Hardy-Weinberg
expectation by a chi-squared test. A level of P < 0.05 was
considered statistically significant.Results and discussions
RAAS has always been an attractive model system for the
study of the genetics of hypertension. Over the course of
lifetime small increase in RAAS activity elevates risk of
hypertension. The ACE gene located on chromosome 17q23, has been suggested by gene targeting and transgenic
studies in mice to play key role in blood pressure regula-
tion.22 Studies in genetically hypertensive and their
normotensive controls revealed a linkage of chromosomal
region containing the ACE gene with blood pressure. This
led to the hypothesis that ACE is a possible candidate gene
for essential hypertension in humans. The DD genotype of
ACE gene was associated with essential hypertension in
different ethnic population. Studies conducted in Japa-
nese,23 Australian,24 Mongolian,25 Pakistanis,26 and Indian
populations14,16 (Bengalese and Sikh population) have sug-
gested an association between ACE- DD polymorphism with
a higher incidence of hypertension. The other studies
conducted in Belgian,27 Dutch,28 Italian29 Caucasians30 and
Bangladesh population18 does not shows any association of
ACE I/D polymorphism with essential hypertension. Ethnic
and geographical variation may influence the ACE I/D
polymorphism with hypertension. Similarly, the Indian
study consist of 105 patients and 192 controls does not show
association of ACE I/D polymorphism with essential hyper-
tension.16 In the present study the DD genotype of ACE gene
is strongly associated with essential hypertension. D-allele
associated with early onset of hypertension in Japanese
subjects.31 Our study represents young hypertensive pa-
tients with 38% of prevalence of DD genotype when
compared to 20% of control subjects. Allele frequency for D
allele is 0.58 in essential hypertension as compared to 0.34
of control subjects and we know that the D allele might
increase the susceptibility to hypertension.32 The present
study exclusively carried out with essential hypertensive
patients. Patients with diabetes mellitus excluded from this
study, because the diabetes itself act as risk factor for the
development of hypertension.33 The study group included
208 essential hypertension patients and 220 controls. The
base line demographic, clinical and laboratory data of the
study population were shown in Table 1. Among patients
121 (58.2%) were men and 87 (41.8%) were women. There
was no significant difference between patients and controls
with respective to age and BMI (P > 0.05). SBH and DBH
were higher in patients when compared to controls
(P  0.05).
Serum total cholesterol, HDL, LDL, VLDL and tri-
glycerides levels are significantly higher in patients when
compared to controls (P  0.05). Blood glucose, serum so-
dium levels also shows difference between patients and
controls (P  0.05). There was no significant difference
between patients and controls in serum creatinine, urea,
potassium and chloride (P  0.05).
In the present study, it was observed that the D-allele of
the ACE gene was in statistically significant association with
essential hypertension as compared to controls subjects.
Table 3 Distribution of ACE genotypes between HTN and
controls.
Patients vs.
controls
Chi-square
(c2)
Odds
ratio
CI 95% P value
L. limit U. limit
DD vs. II 29.07 3.7 2.2 5.9 0.0001*
DD vs. ID 3.04 1.6 0.9 2.6 0.08
DD vs. II þ ID 18.5 2.5 1.6 3.9 0.001*
D vs. I 11.2 1.6 1.2 2.1 0.007*
*P-value <0.05 considered highly significant.
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deviation from hardy Weinberg equilibrium (P < 0.05). The
ACE genotype distribution and allelic frequency among
study subjects are shown in Table 2. In the study popula-
tion, genotypic frequencies of ACE gene for II, ID and DD are
28.3%, 32.6% and 38.9% respectively in essential hyperten-
sive patients as compared to 53.6%, 26.3% and 20%. The
derived allele frequency for D allele is 0.58 in essential
hypertension as compared to 0.34 of control subjects, thus
the D allele frequency is higher in essential hypertension
when compared to controls. It indicates the strong associ-
ation of D-allele with essential hypertension. The ACE ge-
notype distribution between patients and control are shown
in Table 3. The DD vs. II in the patients as compared to
control: X2 Z 29.07, OR Z 3.7, 95% CI Z 2.2e5.9
(P Z 0.0001); DD vs. ID: X2 Z 3.04, OR Z 1.6, 95%
CI Z 0.9e2.6 (P Z 0.08); DD vs. ID: X2 Z 18.5, OR Z 2.5,
95% CI Z 1.6e3.9 (P Z <0.001); D vs. I: X2 Z 11.2,
OR Z 1.6, 95% CI Z 1.2e2.1 (P Z 0.007).Conclusion
In conclusion our results explore the association of DD ge-
notype with essential hypertension. The present study
proves the relation between I/D polymorphism of ACE gene
and essential hypertension in south Indian population.Conflicts of interest
There is no conflict of result.References
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